# What Changed in Weight, Healing, and Survival > Research Peptide Fundamentals | What Changed in Patients — Research Peptide Fundamentals research peptides: how weight, healing, and illness tests differ across four substances. Animal repair leaves human benefits unproved. **HEALTH TESTS / 2026** Studies measured weight, blood sugar, injury repair, and deaths. Four peptides gave different results. Animal improvements don’t establish benefits for people. ### [Tirzepatide](/tirzepatide) ![Tirzepatide research illustration](images/tirzepatide.webp) Adults lost weight and lowered sugar with tirzepatide in phase 3 trials. Those are larger tests. GIP and GLP-1 are gut hormones. ### [Retatrutide](/retatrutide) ![Retatrutide research illustration](images/retatrutide.webp) Early tests found weight loss in adults receiving retatrutide. Phase 2 means an early check for benefits in patients. The lasting effects aren’t yet known. ### [BPC-157](/bpc-157) ![BPC-157 research illustration](images/bpc-157.webp) Injured animals showed signs of faster repair during tests. Human studies remain rare. Those animal improvements cannot prove that your injury heals faster. ### [Thymosin Alpha-1](/thymosin-alpha-1) ![Thymosin Alpha-1 research illustration](images/thymosin-alpha-1.webp) Tests counted deaths during infection and checked the immune system. Survival results have varied between studies. US approval for treatment has not been granted. ## What patient trials showed most clearly Adults receiving tirzepatide weighed less and had improved sugar readings. Early retatrutide tests also found weight loss in treated adults. BPC-157 healing studies mostly tested animals, leaving human benefit unproved. The biggest recent thymosin alpha-1 trial didn’t show clearly better survival [18]. Peptides and proteins both contain linked parts called amino acids. Proteins help build tissue and keep your body working. The peptide name alone cannot establish a shared health benefit. Possible benefit and possible harm need testing separately for each substance. Five questions help put a health claim in its place. Which patients took part, and which health problem changed? How much changed, and what happened without that treatment? A separate trial finding the same benefit adds more confidence. Feeling better after treatment doesn’t always mean treatment caused the change. Illness may improve anyway, or another treatment may help. A fair comparison checks those other causes against the treatment’s effects. The findings are explained here, with no substances offered for sale. ## What animal improvements cannot tell you Human trials check whether treated patients actually become healthier. Tests in dishes check changes in cells outside the body. Animal tests check effects in a different kind of body. An animal’s improvement cannot tell whether treatment makes you healthier. In dishes, tirzepatide stuck more firmly to one type of cell protein [6]. Those proteins recognize hormones, chemicals that guide how the body works. Later trials compared weight loss between hundreds of treated adults [1]. Lab pictures showed retatrutide touching three different types of hormone-recognizing protein [9]. Phase 2 retatrutide trials checked early benefits in people [10][11][12]. BPC-157 tests found growth of blood vessels, tubes carrying blood [16]. Researchers checked animals as well as cells kept in dishes. A review found little testing of healing in people [14]. An earlier thymosin alpha-1 trial suggested fewer deaths during severe infection [22]. The larger phase 3 trial checked that hope in more patients. Deaths differed too little to show clearly that treatment helped [18]. Larger tests can also reveal harm that small tests miss. A review examines past studies rather than treating new patients. Several small hopeful findings can lose support in one larger trial. Changes inside cells may help explain a possible treatment effect. Your chance of getting better still needs testing in patients. ## What the name research peptide tells you about treatment Research peptide is a name, without assurance of treatment approval. FDA has approved tirzepatide for certain uses under a prescription. Retatrutide is still being tested as a possible medicine. Drug approval has not been granted for treatment with BPC-157. Thymosin alpha-1 has approval for medical sale in some countries. The US has not approved that sale as medicine. Permission in another country doesn’t give permission for treatment here. Your question needs the particular substance and the country named. Tirzepatide and retatrutide were made to remain longer in blood. Their hormone effects concern hunger and control of blood sugar. For BPC-157, the copied protein part comes from the stomach. Thymosin alpha-1 affects the immune system, your defense against germs. An animal’s repaired injury cannot prove better healing in people. Patients receiving different treatments may begin with different health problems. Looking back at their medical histories cannot remove those differences. Early phase 2 benefits also don’t mean medical treatment is approved. ## What each substance has shown about better health [Tirzepatide](/tirzepatide) has the most complete human testing of these four. Phase 3 means larger trials after the early benefit checks. Studies compared medicines, checked cell effects, and brought harm counts together [1][3][6][7]. [Retatrutide](/retatrutide) affects three hormones named GIP, GLP-1, and glucagon. Hunger, sugar, and energy use are affected by those hormones. Retatrutide’s phase 2 benefits still need checking in phase 3 [8][11]. [BPC-157](/bpc-157) has animal repair findings with little human healing evidence [13][14][16]. [Thymosin Alpha-1](/thymosin-alpha-1) has uncertain survival results from smaller studies and a larger trial [18][20][22]. The [comparison](/compare) explains what those differences mean for health claims. The [FAQ](/faq) answers common questions about tested benefits and unresolved risks. Each numbered finding leads to its paper through the [references](/references). --- An independent field digest for modern peptide-study methods—literature mapped, uncertainty retained, no products or prescriptions.